4.2 Article

Adoptive Immunotherapy via Donor Lymphocyte Infusions following Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: A Real-World, Retrospective Multicenter Study

Related references

Note: Only part of the references are listed.
Article Oncology

Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study

Siddharth Kunte et al.

Summary: The study demonstrates that haplo-BMT with PTCy is effective in treating myelofibrosis, but splenomegaly >= 22 cm and bone marrow grafts are associated with an increased risk of relapse.

LEUKEMIA (2022)

Article Biophysics

Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysis

D. McLornan et al.

Summary: A retrospective assessment of 4142 patients undergoing allogeneic haematopoietic cell transplant for myelofibrosis between 1995 and 2018 revealed increased activity over time with older recipient age and lower Karnofsky performance status. Utilization of matched unrelated donors increased while myeloablative conditioning decreased. Rates of acute and chronic GVHD decreased, with key factors for worse outcomes being older age, non-matched sibling donors, CMV seropositivity and lower Karnofsky performance status. Overall survival improved over time with stable non-relapse mortality rates.

BONE MARROW TRANSPLANTATION (2021)

Review Oncology

Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party

Donal P. McLornan et al.

Summary: Allogeneic haematopoietic cell transplantation (allo-HCT) remains the only curative approach in myelofibrosis, but relapse rates are still significant. EBMT proposed new definitions and management strategies for graft failure, poor graft function and relapse, as well as recommended systematic monitoring and testing methods to increase accuracy in reporting.

LEUKEMIA (2021)

Article Hematology

Unrelated Cord Blood Transplantation for Patients with Primary or Secondary Myelofibrosis

Marie Robin et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)

Article Medicine, General & Internal

The logrank test

JM Bland et al.

BRITISH MEDICAL JOURNAL (2004)